References
- Giguère V. Orphan nuclear receptors: from gene to function. Endocr Rev 1999;20:689–725
- Germain P, Staels B, Dacquet C, et al. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006;58:685–704
- Germain P, Chambon P, Eichele G, et al; International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760–72
- Takamatsu K, Takano A, Yakushiji N, et al. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRα/β-dual agonist). ChemMedChem 2008;3:780–7
- Haugen BR, Jensen DR, Sharma V, et al. Retinoid X receptor γ-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology 2004;145:3679–85
- Takamatsu K, Takano A, Yakushiji N, et al. Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRα-preferential agonist possessing a sulfonamide moiety. ChemMedChem 2008;3:454–60
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26
- Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2:566–80
- Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2:875–94
- Ogasawara A, Murakami Y, Yakushiji N, et al. Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. Drug Dev Ind Pharm 2011;37:1060–7
- Kusaba J, Kajikawa N, Kawasaki H, et al. Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure. Biopharm Drug Dispos 2012;33:22–9
- Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001;29:141–4
- Imaoka S, Yamada T, Hiroi T, et al. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 1996;51:1041–50
- Gonzalez FJ, Coughtrie M, Tukey RH. Drug metabolism. In: Brunton L, Chabner B, Knollman B, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 12/e. New York: McGraw-Hill; 2011:123–43
- Kotegawa T, Laurijssens BE, Von Moltke LL, et al. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 2002;302:1228–37
- Brown HS, Chadwick A, Houston JB. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos 2007;35:2119–26
- Kobayashi S, Murray S, Watson D, et al. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 1989;38:2795–9
- Sugita O, Sawada Y, Sugiyama Y, et al. Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. A study of tolbutamide-sulfonamide interaction in rats. Biochem Pharmacol 1981;30:3347–54
- Kobayashi K, Urashima K, Shimada N, Chiba K. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 2003;31:833–6
- Wirkner K, Poelchen W. Influence of long-term ethanol treatment on rat liver aniline and p-nitrophenol hydroxylation. Alcohol 1996;13:69–74
- Rencher AC. Principal component analysis. In: Rencher AC, ed. Methods of multivariate analysis, 2/e. New York: John Wiley & Sons Inc; 2002:380–407
- Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;16:2785–91
- Jayakanthan M, Chandrasekar S, Muthukumaran J, Mathur PP. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. J Mol Graph Model 2010;28:455–63
- Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem 2006;281:7614–22